ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Premium IconPremium Help Menu
S&P 500
5,976.97
-1.13%
US Tech 100
21,079.20
-1.25%
Dow Jones
42,197.79
-1.79%
Brent Oil
73.815
0.00%
Bitcoin
105,107.48
-0.98%
Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. AnaptysBio Inc (ANAB) Quote

AnaptysBio Inc

AnaptysBio Inc (ANAB)

NASDAQ
23.32
-0.09
(-0.38%)
Closed June 14 4:00PM
15 min delayed - Upgrade to Realtime
23.32
0.00
(0.00%)
After Hours: 4:25PM
15 min delayed - Upgrade to Realtime

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Premium

Key stats and details

Current Price
23.32
Bid
18.00
Ask
25.00
Volume
441,297
22.455 Day's Range 23.71
12.21 52 Week Range 41.3083
Market Cap
685.153M
Previous Close
23.41
Open
23.20
Last Trade
62396
@
23.32
(priorref)
Last Trade Time
Financial Volume
$ 10,274,880
VWAP
23.2834
Average Volume (3m)
764,634
Shares Outstanding
29,380,496
Dividend Yield
-
PE Ratio
-4.72
Earnings Per Share (EPS)
-4.94
Revenue
91.28M
Net Profit
-145.23M

About AnaptysBio Inc

AnaptysBio Inc is clinical-stage biotechnology company. It is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company develops product candidates to address emerging biological targets using its proprietary, antibody discovery techno... AnaptysBio Inc is clinical-stage biotechnology company. It is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company develops product candidates to address emerging biological targets using its proprietary, antibody discovery technology platform, which is designed to replicate, in vitro, the natural process of antibody generation. Its product candidates are ANB020, ANB019, and Checkpoint receptor agonist. The entity generates revenue from the collaborative research and development arrangements. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
www.anaptysbio.com
Headquarters
Wilmington, Delaware, USA
Founded
-
AnaptysBio Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker ANAB. The last closing price for AnaptysBio was $23.41. Over the last year, AnaptysBio shares have traded in a share price range of $ 12.21 to $ 41.3083.

AnaptysBio currently has 29,380,496 shares outstanding. The market capitalization of AnaptysBio is $687.80 million. AnaptysBio has a price to earnings ratio (PE ratio) of -4.72.

Ask ADVFN Intelligence (AI)

ANAB Latest News

More News

Form 8-K - Current report
Edgar (US Regulatory)
June 03 2025
ANAB (-0.38%)

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Edgar (US Regulatory)
May 05 2025
ANAB (-0.38%)

Form 8-K - Current report
Edgar (US Regulatory)
May 05 2025
ANAB (-0.38%)

Form ARS - Annual Report to Security Holders
Edgar (US Regulatory)
April 29 2025
ANAB (-0.38%)

Form DEF 14A - Other definitive proxy statements
Edgar (US Regulatory)
April 29 2025
ANAB (-0.38%)
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
12.039.5349929544421.2924.4120.9373238523.61655818CS
42.914.201762977520.4224.679919.0477897921.95314562CS
125.91533.984487216317.40524.679915.476463419.94609125CS
268.6859.289617486314.6424.679912.2184412617.8819375CS
52-0.66-2.7522935779823.9841.308312.2162662621.21109294CS
1562.069.6895578551321.2641.308312.2138770921.79453918CS
2605.2428.98230088518.0841.308312.2134497522.64341853CS

ANAB - Frequently Asked Questions (FAQ)

What is the current AnaptysBio share price?
The current share price of AnaptysBio is $ 23.32
How many AnaptysBio shares are in issue?
AnaptysBio has 29,380,496 shares in issue
What is the market cap of AnaptysBio?
The market capitalisation of AnaptysBio is USD 687.8M
What is the 1 year trading range for AnaptysBio share price?
AnaptysBio has traded in the range of $ 12.21 to $ 41.3083 during the past year
What is the PE ratio of AnaptysBio?
The price to earnings ratio of AnaptysBio is -4.72
What is the cash to sales ratio of AnaptysBio?
The cash to sales ratio of AnaptysBio is 7.51
What is the reporting currency for AnaptysBio?
AnaptysBio reports financial results in USD
What is the latest annual turnover for AnaptysBio?
The latest annual turnover of AnaptysBio is USD 91.28M
What is the latest annual profit for AnaptysBio?
The latest annual profit of AnaptysBio is USD -145.23M
What is the registered address of AnaptysBio?
The registered address for AnaptysBio is 1209 ORANGE STREET, WILMINGTON, DELAWARE, 19801
What is the AnaptysBio website address?
The website address for AnaptysBio is www.anaptysbio.com
Which industry sector does AnaptysBio operate in?
AnaptysBio operates in the PHARMACEUTICAL PREPARATIONS sector

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
RBNERobin Energy Ltd
$ 13.85
(313.43%)
101.81M
OPOceanPal Inc
$ 1.63
(125.45%)
80.28M
LGHLWLion Group Holding Ltd
$ 0.0052
(116.67%)
6.87M
NEONNeonode Inc
$ 16.83
(68.47%)
4.78M
ICONIcon Energy Corporation
$ 2.90
(62.01%)
59.04M
SBETSharpLink Gaming Inc
$ 9.2275
(-71.63%)
41.92M
AIHSSenmiao Technology Ltd
$ 0.381
(-63.01%)
16.8M
CHSNChanson International Holding
$ 0.22
(-60.00%)
15.15M
KWMK Wave Media Ltd
$ 2.91
(-50.43%)
2.59M
JZXNJiuzi Holdings Inc
$ 1.56
(-46.39%)
2.24M
HCTIHealthcare Triangle Inc
$ 0.0201
(-33.00%)
856.89M
GNLNGreenlane Holdings Inc
$ 0.0101
(-34.42%)
792.34M
CGBSCrown LNG Holdings Ltd
$ 0.1104
(31.43%)
788.42M
TSLLDirexion Daily TSLA Bull 2X Trust ETF
$ 12.655
(3.81%)
246.13M
NVDANVIDIA Corporation
$ 141.97
(-2.09%)
180.81M

ANAB Discussion

View Posts
tw0122 tw0122 4 months ago
ANAB $16.49 + 33% ...  will host an investor call and live webcast to review top-line data from the global Phase 2b RENOIR clinical trial of investigational rosnilimab, a depleter and agonist of PD-1+ T cells, for moderate-to-severe rheumatoid arthritis on Wednesday, Feb. 12, 2025, at 8:30am ET / 5:30am PT....
👍️ 1
Monksdream Monksdream 9 months ago
ANAB definite uptrend
👍️0
gfp927z gfp927z 3 years ago
HighPeaks, The NY Times article was high profile, but the connection to ANAB isn't readily apparent.

Even with the partial sale/monetization of the revenue stream from dostarlimab in December, the drug is also being studied by Glaxo for other cancer types (endometrial, non-small cell lung, ovarian, and mismatch repair deficient solid tumors). One question to answer is whether the monetization deal with Sagard was only for colorectal, or for all the indications? Probably for all, but I'll have to do more research.

ANAB has numerous other programs and a large pile of cash, so looks interesting. But investing in biotech requires a ton of research, but even then you still don't know what you have, and landmines are everywhere. Better to invest in 'what you know', as Buffett recommends :o)




---
👍️0
HighPeaks HighPeaks 3 years ago
Thanks TP. Yeah this has the potential to really be a big mover. So surprised no one has made the connection between this potential miracle drug and $ANAB receiving royalties on it(as it’s originator). GSK is the collaborator who has just commercialized it but it’s ANAB invention.
👍️0
tedpeele tedpeele 3 years ago
Tremendous find HighPeaks. .You have been early on quite a few big movers. I'm thinking this is yet another one.

Will be watching this closely...thanks.
👍️0
HighPeaks HighPeaks 3 years ago
According to this link ANAB gets 8-25% royalties from Dostarlimab. This drug has recently shown phenomenal results in a trial at Memorial Sloan Kettering Hospital. All patients fully recovered from rectal cancer.
https://www.globenewswire.com/fr/news-release/2020/10/26/2114250/0/en/AnaptysBio-and-GlaxoSmithKline-Amend-Strategic-Immuno-Oncology-Collaboration.html
👍️0
TFMG TFMG 5 years ago

$ANAB | #Anaptysbio Spikes After Drug Designation


Nice spike in the afterhours session, lets hope we
can get some continuation tomorrow.
Target $29.00 to Fib Golden Pocket
Also a very large gap to fill at $35.00
AnaptysBio gets orphan drug designation of imsidolimab for pustular psoriasis
PLEASE GIVE US A LIKE IF YOU FIND OUR CONTENT HELPFUL, THANK YOU.


👍️0
LoveItInBishop LoveItInBishop 6 years ago
RSI @ 16. laughable. Zacks has positive take. https://finance.yahoo.com/news/anaptysbio-enters-oversold-territory-135501475.html
👍️0
ClayTrader ClayTrader 6 years ago
* * $ANAB Video Chart 11-13-19 * *

Link to Video - click here to watch the technical chart video

👍️0
ClayTrader ClayTrader 6 years ago
* * $ANAB Video Chart 11-08-19 * *

Link to Video - click here to watch the technical chart video

👍️0
waterchaser waterchaser 6 years ago
LOL! Twitter PnD. Buyer beware.
👍️0
420man 420man 6 years ago
Once the real bounce starts it will be fast....
👍️0
Crazy Money Crazy Money 6 years ago
$10 to da moon
👍️0
420man 420man 6 years ago
This will bounce..... 15 AH
👍️0
RJ Trotts RJ Trotts 6 years ago
trying to bounce back over $11, hoping for more
👍️0
TaxiCaT TaxiCaT 6 years ago
Ouch -
👍️0
celle celle 6 years ago
Nothing happen here?
👍️0
manny371 manny371 7 years ago
This stock is making noise! Bought in Sept $ANAB
👍️0

Your Recent History

NASDAQ
ANAB
AnaptysBio
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub
United States
Company
Business
Popular
Get The App
App Store
Google Play

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2025 ADVFN Ltd - All Rights Reserved

Go Ad-Free

Subscribe to Ad free and enjoy an ad-free experience

No Ads

Try Now

Keep the Ads